Scholarlink

<p>Lerodalcibep (lerodalcibep-liga; LEROCHOL<sup>®</sup>), a subcutaneously administered third-generation proprotein convertase subtilisin/kexin type&#xa0;9 (PCSK9) inhibitor, is being developed by LIB Therapeutics for the treatment of hypercholesterolaemia. Lerodalcibep received its first approval on 12&#xa0;December 2025 in the USA, as an adjunct to diet and exercise, to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolaemia, including heterozygous familial hypercholesterolaemia. Lerodalcibep is in preregistration for hypercholesterolaemia in the EU. Lerodalcibep is administered as a once-monthly subcutaneous injection. This article summarizes the milestones in the development of lerodalcibep leading to this first approval for the treatment of adults with hypercholesterolaemia.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Lerodalcibep: First Approval

  • 期刊论文

  • 发表日期：

    2026年4月7日

查看全文
  • Amy Zhuang-Yan,
  • Hannah A. Blair

摘要

Lerodalcibep (lerodalcibep-liga; LEROCHOL®), a subcutaneously administered third-generation proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, is being developed by LIB Therapeutics for the treatment of hypercholesterolaemia. Lerodalcibep received its first approval on 12 December 2025 in the USA, as an adjunct to diet and exercise, to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolaemia, including heterozygous familial hypercholesterolaemia. Lerodalcibep is in preregistration for hypercholesterolaemia in the EU. Lerodalcibep is administered as a once-monthly subcutaneous injection. This article summarizes the milestones in the development of lerodalcibep leading to this first approval for the treatment of adults with hypercholesterolaemia.